Start a Conversation.

Five service areas: Drug Response Screening, Combination Therapy Profiling, Ex Vivo Clinical Trial Support, Functional Precision Oncology Research, and Customised Solutions. Every project is designed around your biological question, study objectives, and translational goals rather than a fixed catalogue package.

On our platform, an organoid represents an advanced 3D cell culture model that retains key structural and biological characteristics of human tumor architecture. Compared with flat 2D monolayer cultures, this 3D cell culture approach provides a physiologically relevant system for ex vivo drug response evaluation prior to costly in vivo studies.

No. All 3DxCell services are for research use only. Results support drug development, translational oncology, and clinical research; they are not intended for clinical diagnosis or to direct treatment decisions for an individual patient.

No. 3DxCell provides research services to pharmaceutical companies, biotech firms, academic institutions, and clinical research partners. Patients interested in organoid-based research should speak with their treating oncologist.

Yes. We are based in Lund, Sweden and work with pharma, biotech, and academic groups across Europe and beyond. Samples are shipped to our facility under validated conditions, and all reporting is delivered digitally.

With a free, informal scientific consultation of roughly 30–60 minutes, where we assess feasibility and ask the right scientific questions. A written proposal follows within 3–5 business days; after agreement, kickoff and sample logistics take 1–2 weeks.

Yes, and we encourage it. We are happy to sign a mutual NDA before any substantive scientific discussion or data sharing. Contact us and we will respond within 1 business day.

No. Every project is scoped individually: the number of models, compounds, assay complexity, and deliverables all shape it. You receive a written proposal with transparent pricing before any commitment, and the first conversation is free.

No. The request form captures the shape of your study (service area, number of compounds and models, and which deliverables you need), so we can scope it quickly. Anything shown there is indicative; only the written proposal is binding.

Most standard studies run approximately 7–10 weeks from kickoff to final report delivery. Larger cohort studies under Ex Vivo Clinical Trial Support may require extended timelines, which are fully defined in the proposal before work begins.

Results are generated for you and delivered to you. Ownership of data and of any resulting intellectual property is set out in the agreement signed before kickoff, and everything shared in both directions is treated as confidential.

Yes. We work with academic groups on mechanistic studies, biomarker research, resistance modeling, and translational research projects. Academic collaboration frameworks are available. Tell us about the study and we will scope it accordingly.

We work across a broad spectrum of solid tumors encompassing diverse histopathological and genomic backgrounds. Feasibility and study design are evaluated during the initial scientific consultation based on your specific research objectives.

Yes. Organoid Establishment from eligible samples can be built into the scope, with cohort-level model tracking where relevant. Feasibility depends on the indication and on sample access, so it is the first thing we discuss.

A Comprehensive Final Study Report covering study design, assay conditions, controls, analysis methodology, statistical evaluation, and an integrated interpretation of the results, with raw and processed data as accompanying files. Depending on the service, Drug Response Analysis, Morphology Assessment, Histopathology & Marker Profiling, and Genomic Profiling are included or optional.

Yes. Combination Therapy Profiling characterises functional responses to combination therapies and includes Combination Response Analysis: combination response matrices, graphical summaries, and synergy scoring using established models (Loewe, Bliss, HSA) where it suits the study design.

Yes. Ex Vivo Clinical Trial Support is built for cohort-level work: response distribution across the cohort, differential response patterns, candidate responder subgroups, and biomarker-informed stratification to support clinical development strategies.

Model characterisation is a core component of our 3D cell culture workflow: histopathological assessment, genomic profiling, and quality verification are completed prior to drug testing.

Our workflows are standardized and every study is documented through structured research reporting, which is a solid basis for a regulatory package. Bring your regulatory context into the scoping conversation. The documentation scope is easiest to set before the study design is fixed.